Avenda Systems

Avenda Health's Revolutionary AI Mapping Tool for Prostate Cancer Achieves Landmark Category III CPT Code Designation

Retrieved on: 
Wednesday, November 1, 2023

CULVER CITY, Calif., Nov. 1, 2023 /PRNewswire/ -- The American Medical Association (AMA) has announced its 2024 Current Procedural Terminology (CPT) code set will include a new Category III code for Avenda Health's innovative Unfold AI™, a cancer AI platform that creates new clinically meaningful insights to aid physicians and patients in making informed treatment decisions. CPT codes are used to report medical procedures and services for processing claims, conducting research, evaluating utilization and developing medical guidelines. The Category III designation is a temporary code for new and developing technologies.

Key Points: 
  • Reimbursement code improves access to personalized prostate cancer care with Avenda Health's AI cancer mapping platform, Unfold AI™
    CULVER CITY, Calif., Nov. 1, 2023 /PRNewswire/ -- The American Medical Association (AMA) has announced its 2024 Current Procedural Terminology (CPT) code set will include a new Category III code for Avenda Health 's innovative Unfold AI™, a cancer AI platform that creates new clinically meaningful insights to aid physicians and patients in making informed treatment decisions.
  • The Category III designation is a temporary code for new and developing technologies.
  • "The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients."
  • Avenda plans to expand to major teaching hospitals and urology practices nationwide, ensuring widespread access to advanced cancer care solutions.

First AI-Powered Precision Oncology Platform for Prostate Cancer Care, iQuestTM, Receives FDA Clearance

Retrieved on: 
Wednesday, December 7, 2022

CULVER CITY, Calif., Dec. 7, 2022 /PRNewswire/ -- Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today announced its cancer management platform, iQuestTM, has received 510(k) clearance by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • CULVER CITY, Calif., Dec. 7, 2022 /PRNewswire/ -- Avenda Health , an AI healthcare company creating the future of personalized prostate cancer care, today announced its cancer management platform, iQuestTM, has received 510(k) clearance by the U.S. Food and Drug Administration (FDA).
  • The platform enables a physician to make decisions that consider the cancer extent rather than treating the whole organ.
  • "In order for a doctor to treat focally, they need to know where cancer is and the healthy tissue to avoid.
  • This clearance will go a long way not only for our company but for the future of prostate cancer care."

Avenda Health Receives FDA Investigational Device Exemption for AI-enabled Prostate Cancer Therapy

Retrieved on: 
Tuesday, August 9, 2022

CULVER CITY, Calif., Aug. 9, 2022 /PRNewswire/ -- Avenda Health, an AI healthcare company creating the future of prostate cancer care, today announced its FocalPoint ablation system powered by iQuest, a patient management AI software, has received investigational device exemption (IDE) from the US Food and Drug Administration (FDA). The IDE will allow these two technologies to be used together in a randomized control trial to show superiority over standard of care for the treatment of prostate cancer.

Key Points: 
  • "Our mission is to advance prostate cancer therapy so patients no longer need to choose between treatment or quality of life," said Dr. Shyam Natarajan, co-founder and CEO of Avenda Health.
  • FocalPoint is Avenda Health's focal laser ablation system designed to treat localized prostate cancer in-office while preserving quality of life.
  • In 2021, the FDA granted Avenda Health with Breakthrough Device Designation, indicating there is a high likelihood the Avenda Health technology will be better than the standard of care.
  • In each of its technologies, Avenda Health is building a more personalized and targeted standard of care for prostate cancer.

Avenda Health Announces Additions to Company’s Board of Directors and Advisory Board

Retrieved on: 
Thursday, July 11, 2019

Avenda Health, a software and medical device company developing an AI-based focal laser ablation system for prostate treatment, today announced additions to the companys board of directors and its advisory board.

Key Points: 
  • Avenda Health, a software and medical device company developing an AI-based focal laser ablation system for prostate treatment, today announced additions to the companys board of directors and its advisory board.
  • Dr. Simon Stertzer, a cardiologist, professor and investigator with vast contributions in cardiology, will serve as a medical advisor.
  • Mr. Kleins experience in the commercialization of artificial intelligence and machine learning in imaging will be propitious for Avenda.
  • Avenda Health is the only image-guided ablation system (pending FDA clearance) that leverages artificial intelligence to optimize tumor treatment, minimizing side effects for the patient.

Office-based, Non-invasive Prostate Cancer Treatment Is Top Winner of 2019 SPIE Startup Challenge at Photonics West

Retrieved on: 
Tuesday, February 12, 2019

BELLINGHAM, Wash., Feb. 12, 2019 /PRNewswire-PRWeb/ --A technology company that aims to shift prostate-cancer treatment from an invasive surgical setting to a brief, office-based visit, won the top award at the 9th annual SPIE Startup Challenge at Photonics West on Wednesday, 6 February.

Key Points: 
  • BELLINGHAM, Wash., Feb. 12, 2019 /PRNewswire-PRWeb/ --A technology company that aims to shift prostate-cancer treatment from an invasive surgical setting to a brief, office-based visit, won the top award at the 9th annual SPIE Startup Challenge at Photonics West on Wednesday, 6 February.
  • Avenda Health's Brittany Berry-Pusey presented the winning pitch, nabbing a combined first prize of $15,000.
  • Avenda Health's win, she added, will help the nascent company with its next steps: "We are treating men with prostate cancer.
  • And it's only possible because of photonics, because of the lasers that we are using."

Office-based, Non-invasive Prostate Cancer Treatment Is Top Winner of 2019 SPIE Startup Challenge at Photonics West

Retrieved on: 
Tuesday, February 12, 2019

BELLINGHAM, Wash. and SAN FRANCISCO, Feb. 12, 2019 /PRNewswire/ --A technology company that aims to shift prostate-cancer treatment from an invasive surgical setting to a brief, office-based visit, won the top award at the 9thannual SPIE Startup Challenge at Photonics West on Wednesday, 6 February.

Key Points: 
  • BELLINGHAM, Wash. and SAN FRANCISCO, Feb. 12, 2019 /PRNewswire/ --A technology company that aims to shift prostate-cancer treatment from an invasive surgical setting to a brief, office-based visit, won the top award at the 9thannual SPIE Startup Challenge at Photonics West on Wednesday, 6 February.
  • Avenda Health's Brittany Berry-Pusey presented the winning pitch, nabbing a combined first prize of $15,000.
  • Avenda Health's win, she added, will help the nascent company with its next steps: "We are treating men with prostate cancer.
  • And it's only possible because of photonics, because of the lasers that we are using."